{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:20Z","timestamp":1787071040613,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Skin reactions after transarterial chemoembolization (TACE) with anthracyclines are rare and mostly limited to small areas. We describe a 56-year-old male with hepatocellular carcinoma treated with epirubicin chemoembolization. Immediately the procedure, pain on the right side and an extended livedo reticularis-like skin reaction appeared. Since dexrazoxane, a topoisomerase-II catalytic-cycle inhibitor, has been shown to be effective in preventing or reducing skin necrosis and ulceration following anthracycline extravasation, the drug was administered 8 h after TACE and repeated in the following 2 days. Due to marked extrahepatic diffusion of epirubicin as evidenced by computed tomography imaging, the patient showed signs of systemic organ involvement. The critically ill patient required close follow-up and intensified treatment including blood supply and pulmonary drainage of a pleural effusion. The patient presented a significant clinical improvement of the skin lesions and resolution of organ involvement with normalization of laboratory parameters after dexrazoxane. In conclusion, adverse extended skin reactions and severe systemic effects related to anthracyclines diffusion could be properly treated with dexrazoxane infusion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_574_20","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T03:43:03Z","timestamp":1637552583000},"page":"S501-S506","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Dexrazoxane for rapid extended livedo reticularis-like skin reaction due to systemic epirubicin diffusion during transcatheter arterial chemoembolization procedure for hepatocellular carcinoma"],"prefix":"10.4103","volume":"18","author":[{"given":"Andrea","family":"Giampreti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Luc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariapina","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Baldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Eleftheriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"Contessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Faraoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Butera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bacis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-63-20241021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diii.2017.09.005","article-title":"Dexrazoxane prevents skin necrosis in non-target embolization of falciform artery during transcatheter arterial chemoembolization (TACE)","volume":"99","author":"Stalder","year":"2018","journal-title":"Diagn Interv Imaging"},{"key":"R2-63-20241021","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1607-551X(09)70082-8","article-title":"Supraumbilical skin rash and fat necrosis after transcatheter arterial chemoembolization: A case report","volume":"20","author":"Lin","year":"2004","journal-title":"Kaohsiung J Med Sci"},{"key":"R3-63-20241021","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1440-1746.1998.tb00670.x","article-title":"Case report: Steatonecrosis in the upper abdomen following transcatheter arterial embolization for hepatocellular carcinoma","volume":"13","author":"Umemura","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"R4-63-20241021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00204147","article-title":"Embolization of the hepatic falciform artery to prevent supraumbilical skin rash during transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"18","author":"Ueno","year":"1995","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R5-63-20241021","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00270-012-0356-6","article-title":"Supraumbilical subcutaneous fat necrosis after transcatheter arterial chemoembolization with drug-eluting beads: Case report and review of the literature","volume":"36","author":"Kim","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R6-63-20241021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/028418500127345596","article-title":"Hepatic falciform artery. Angiographic findings in 25 patients","volume":"41","author":"Baba","year":"2000","journal-title":"Acta Radiol"},{"key":"R7-63-20241021","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1345\/aph.1M636","article-title":"Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation","volume":"44","author":"Tyson","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R8-63-20241021","first-page":"3680","article-title":"Treatment of anthracycline extravasation with dexrazoxane","volume":"6","author":"Langer","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R9-63-20241021","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/ijcp.12103","article-title":"Dexrazoxane efficacy for anthracycline extravasation: Use in UK clinical practice","volume":"67","author":"Muthuramalingam","year":"2013","journal-title":"Int J Clin Pract"},{"key":"R10-63-20241021","doi-asserted-by":"crossref","first-page":"573","DOI":"10.4103\/0973-1482.77081","article-title":"Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation","volume":"6","author":"Arroyo","year":"2010","journal-title":"J Cancer Res Ther"},{"key":"R11-63-20241021","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0006-2952(93)90514-W","article-title":"Antagonistic effect of the cardioprotector (+)-1,2-bis (3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)","volume":"46","author":"Sehested","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"R12-63-20241021","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0006-2952(95)02241-4","article-title":"Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle","volume":"51","author":"Sehested","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"R13-63-20241021","first-page":"4909","article-title":"Inhibition of intracellular topoisomerase II by antitumor bis (2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors","volume":"51","author":"Ishida","year":"1991","journal-title":"Cancer Res"},{"key":"R14-63-20241021","first-page":"4903","article-title":"Inhibition of topoisomerase II by antitumor agents bis (2,6-dioxopiperazine) derivatives","volume":"51","author":"Tanabe","year":"1991","journal-title":"Cancer Res"},{"key":"R15-63-20241021","first-page":"140","article-title":"Dexrazoxane: How it works in cardiac and tumor cells","volume":"7","author":"Hasinoff","year":"2007","journal-title":"Is it a prodrug or is it a drug? Cardiovasc Toxicol"},{"key":"R16-63-20241021","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-003-0619-7","article-title":"Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide","volume":"52","author":"Schroeder","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-63-20241021","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00203545","article-title":"Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors","volume":"5","author":"Vogel","year":"1987","journal-title":"Invest New Drugs"},{"key":"R18-63-20241021","first-page":"5255","article-title":"Pharmacokinetics of(+)-1,2-di (3,5-dioxopiperazin-1-yl) propane intravenous infusions in adult cancer patients","volume":"42","author":"Earhart","year":"1982","journal-title":"Cancer Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_574_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:40Z","timestamp":1787067640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_574_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":18,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_574_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}